Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma

  • Abramson J
  • Hellmann M
  • Barnes J
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Author-supplied keywords

  • Adult
  • Aged
  • Antibodies,Monoclonal
  • Antibodies,Monoclonal,Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols
  • Central Nervous System
  • Central Nervous System Neoplasms
  • Cyclophosphamide
  • Disease-Free Survival
  • Doxorubicin
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections,Intravenous
  • Lymphoma
  • Lymphoma,Large B-Cell,Diffuse
  • Male
  • Methotrexate
  • Middle Aged
  • Prednisone
  • Recurrence
  • Risk
  • Risk Factors
  • Survival Rate
  • Vincristine
  • administration & dosage
  • adverse effects
  • analysis
  • complications
  • drug therapy
  • methods
  • mortality
  • pathology
  • prevention & control
  • secondary
  • therapeutic use
  • therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • PMID: 20564149

Authors

  • J S Abramson

  • M Hellmann

  • J A Barnes

  • P Hammerman

  • C Toomey

  • T Takvorian

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free